Trial Profile

A Phase 2, Randomized, Double-blinded, Placebo-controlled, Dose-Response Study of Oral (Z)-Endoxifen in Premenopausal Women With Measurable Breast Density

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 04 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Endoxifen (Primary)
Indications Breast cancer
Focus Therapeutic Use
Acronyms Karisma-Endoxifen study
Sponsors Atossa Therapeutics

Most Recent Events

25 Mar 2025 Results presented in an Atossa Therapeutics media release.
25 Apr 2024 Status changed from recruiting to active, no longer recruiting.
25 Jan 2023 According to an Atossa Therapeutics media release, the company announced last fall that the study was approximately 40% enrolled and enrolment of all 240 patients expects to complete by the end of the year.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com